

## DESCRIPTION


<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human Endocan in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 20% cross-reactivity with recombinant mouse Endocan is observed.
<b>Source</b>	Polyclonal Goat IgG
<b>Purification</b>	Antigen Affinity-purified
<b>Immunogen</b>	Mouse myeloma cell line NS0-derived recombinant human Endocan/ESM-1 Trp20-Arg184 Accession # Q9NQ30
<b>Endotoxin Level</b>	<0.10 EU per 1 µg of the antibody by the LAL method.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
<b>Western Blot</b>	1 µg/mL	See Below
<b>Neutralization</b>	Measured by its ability to neutralize Endocan/ESM-1-mediated adhesion of the Jurkat human acute T cell leukemia cell line. The Neutralization Dose (ND <sub>50</sub> ) is typically 1-4 µg/mL in the presence of 20 µg/mL Recombinant Human Endocan/ESM-1.	

## DATA



## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 0.2 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## BACKGROUND

Endocan, also known as endothelial-cell specific molecule-1 (ESM-1), is a secreted cysteine-rich dermatan sulfate (DS) proteoglycan primarily expressed by endothelial cells within the vascular capillary network in kidney and in the alveolar walls of the lung (1). Endocan expression has also been detected in different epithelia and in adipocytes (2, 3). The expression of endocan is upregulated by TNF- $\alpha$ , IL-1 $\beta$ , or lipopolysaccharide and down-regulated by IFN- $\gamma$  (1). The human Endocan gene encodes a 184 amino acid (aa) residues precursor protein with a 19 aa hydrophobic signal peptide and a 165 aa mature region with 18 Cysteine residues (1). The DS chain is covalently attached to serine 137 (4). Endocan has been shown to bind CD11a/CD18 integrin (also known as lymphocyte function-associated antigen-1, LFA-1) on human lymphocytes, monocytes and Jurkat cells, inhibiting its binding to ICAM-1 and reducing LFA-1-mediated leukocyte activation (5). Endocan binds via its DS chain to hepatocyte growth factor (HGF) to enhance HGF mitogenic activity (3, 6). Genetically engineered cells overexpressing endocan has been shown to induce tumor formation, suggesting that Endocan may be involved in the pathophysiology of tumor growth *in vivo* (3, 6). Circulating Endocan can be detected in the serum from healthy subjects. In patients with lung cancer or acute and severe sepsis, elevated Endocan concentrations have been reported (2, 6).

## References:

1. Lassalle, P. *et al.* (1996) *J. Biol. Chem.* **271**:20458.
2. Bechard, D. *et al.* (2000) *J. Vasc. Res.* **37**:417.
3. Wellner, M. *et al.* (2003) *Horm. Metab. Res.* **35**:217.
4. Bechard, D. *et al.* (2001) *J. Biol. Chem.* **276**:48341.
5. Bechard, D. *et al.* (2001) *J. Immunol.* **167**:3099
6. Scherpereel, A. *et al.* (2003) *Cancer Res.* **63**:6084.